To selectively kill tumor cells, the reengineered anthrax toxin targets three over-expressed proteins: The urokinase-type plasminogen activator (uPA) and its receptor (uPAR), and the metalloproteinases (MMPs). Here, PLAUR is linked to neoplasm.